American Society for Radiation Oncology: Radiopharmaceutical Therapy Offers Promise for People With Tough-To-Treat Meningioma Brain Tumors
September 29, 2024
September 29, 2024
ARLINGTON, Virginia, Sept. 29 (TNSres) -- The American Society for Radiation Oncology issued the following news release:
* * *
Phase 2 clinical trial finds 177Lu-Dotatate may extend progression-free survival for patients with no other options to manage recurrent disease
* * *
A radiopharmaceutical therapy that has successfully extended progression-free survival for patients with neuroendocrine tumors shows early promise for delivering similar b . . .
* * *
Phase 2 clinical trial finds 177Lu-Dotatate may extend progression-free survival for patients with no other options to manage recurrent disease
* * *
A radiopharmaceutical therapy that has successfully extended progression-free survival for patients with neuroendocrine tumors shows early promise for delivering similar b . . .